| 2007 | 2008 | 2009 | 2010 | 2011 | |
|---|---|---|---|---|---|
| Revenues | 344.8 | 326.9 | 428.9 | 379.5 | 373.5 |
| Sales | 332.9 | 321.8 | 419.1 | 375.6 | 363.6 |
| excl.Tamiflu® | 294.3 | 313.4 | 342.9 | 357.4 | 354.9 |
| Tamiflu® | 38.7 | 8.4 | 76.2 | 18.2 | 8.7 |
| Ordinary sales | 10.2 | 7.1 | 36.2 | 1.6 | 5.4 |
| Govt. stockpile etc. | 28.5 | 1.3 | 40.0 | 16.6 | 3.3 |
| Other operating revenues | 11.9 | 5.1 | 9.8 | 3.9 | 9.9 |
| Cost of sales | 137.3 | 127.0 | 192.9 | 162.4 | 157.5 |
| (% of Sales) | 41.2 | 39.5 | 46.0 | 43.2 | 43.3 |
| Gross profit | 207.5 | 199.9 | 236.1 | 217.1 | 216.0 |
| (% of Revenues) | 60.2 | 61.2 | 55.0 | 57.2 | 57.8 |
| SG&A (excl. R&D) expenses | 86.6 | 95.1 | 98.2 | 96.2 | 97.7 |
| (% of Revenues) | 25.1 | 29.1 | 22.9 | 25.3 | 26.2 |
| R&D expenses | 54.2 | 53.2 | 55.3 | 54.7 | 55.9 |
| (% of Revenues) | 15.7 | 16.3 | 12.9 | 14.4 | 15.0 |
| Operating income | 66.7 | 51.6 | 82.6 | 66.2 | 62.4 |
| (% of Revenues) | 19.3 | 15.8 | 19.3 | 17.4 | 16.7 |
| Non-operating income | 4.3 | 9.9 | 9.4 | 2.4 | 2.3 |
| Non-operating expenses | 3.3 | 4.2 | 1.6 | 3.5 | 1.2 |
| Recurring profit | 67.7 | 57.3 | 90.4 | 65.1 | 63.6 |
| (% of Revenues) | 19.6 | 17.5 | 21.1 | 17.2 | 17.0 |
| Extraordinary gain | 0.3 | 7.3 | 0.3 | 0.6 | 0.0 |
| Extraordinary loss | 1.6 | 1.4 | 1.3 | 0.0 | 6.5 |
| Income before income taxes etc. | 66.4 | 63.1 | 89.4 | 65.7 | 57.1 |
| (% of Revenues) | 19.3 | 19.3 | 20.8 | 17.3 | 15.3 |
| Net income | 40.1 | 39.3 | 56.6 | 41.4 | 35.2 |
| (% of Revenues) | 11.6 | 12.0 | 13.2 | 10.9 | 9.4 |
- Revenues/Overseas Revenues Ratio
- Operating Income (Billions of Yen)/Operating Income to Revenues (%)
- Revenues (Billions of Yen)/Operating Income Ratio (%)/Recurring Profit Ratio (%)/Net Income Ratio (%)
- R&D Expenses (Billions of Yen)/R&D Expenses Ratio (%)
- Cost Structure (%)
Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.
Variance and % are calculated based on amounts shown.
